Brise Pharmaceuticals Announces Global License Agreement with AbbVie to Advance the Next-Generation of Migraine Therapies
PR Newswire•02/11/2026•09:00 ET
0
Key Highlights
- ➤AbbVie to lead global development and commercialization for two preclinical migraine programs
- ➤Brise- AbbVie collaboration could generate up to US $757 million plus future-sales royalties
- ➤Brise responsible for discovery efforts under the global license agreement
- ➤Brise says several near-term milestones have already been achieved
Expert Statements
Guochun Li, Chief Executive Officer of Brise Pharmaceuticals
“This collaboration represents an important validation of our research platform in migraine and advances our mission to deliver potentially transformative medicines to patients.”
Guochun Li, Chief Executive Officer of Brise Pharmaceuticals
“By partnering with a global leader like AbbVie, we can maximize the value of our discovery engine while continuing to invest in the next wave of innovative therapies.”
Brise Pharmaceuticals Announces Global License Agreement with AbbVie to Advance the Next-Generation of Migraine Therapies PR Newswire
BEIJING, Nov. 2, 2026 /PRNewswire/ -- Brise Pharmaceuticals Co., Ltd. (Brise) today provided an update on its exclusive license agreement with AbbVie (NYSE: ABBV), which the companies entered in 2024. Under the terms of the collaboration agreement, Brise is responsible for discovery efforts and AbbVie will lead global development and commercialization activities for two of Brise's preclinical migraine programs.
Get started
Create a free account to read the full story.